119 related articles for article (PubMed ID: 26334457)
41. Multifocal Motor Neuropathy Associated with Infliximab.
Rowan CR; Tubridy N; Cullen G
J Crohns Colitis; 2015 Dec; 9(12):1174-5. PubMed ID: 26223843
[TBL] [Abstract][Full Text] [Related]
42. An Old Bridge to the Newer Biologics: Cyclosporine for Rescue Therapy in Acute Severe Ulcerative Colitis.
Ashat D; Jain A; Weaver KN; Long MD; Herfarth HH; Barnes EL
Dig Dis Sci; 2022 Dec; 67(12):5439-5443. PubMed ID: 36125593
[No Abstract] [Full Text] [Related]
43. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
Kobayashi T; Suzuki Y; Motoya S; Hirai F; Ogata H; Ito H; Sato N; Ozaki K; Watanabe M; Hibi T
J Gastroenterol; 2016 Mar; 51(3):241-51. PubMed ID: 26162647
[TBL] [Abstract][Full Text] [Related]
44. [Has colectomy for moderate-severe active ulcerative colitis decreased?].
Besser N; Chacón E; Iglesias A; Álvarez-Lobos M; Pavez C; Villalón C; Urrejola G; Zúñiga Á; Molina ME; Miguieles R; Bellolio F
Rev Med Chil; 2023 Mar; 151(3):313-320. PubMed ID: 38293876
[No Abstract] [Full Text] [Related]
45. Infliximab or cyclosporine for severe ulcerative colitis.
Hanauer SB
Gastroenterology; 2005 Oct; 129(4):1358-9; author reply 1359. PubMed ID: 16230092
[No Abstract] [Full Text] [Related]
46. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
47. Infliximab in refractory severe ulcerative colitis: a case report.
Bossa F; Caserta L; Selvaggi F; Riegler G
Minerva Gastroenterol Dietol; 2005 Sep; 51(3):261-2. PubMed ID: 16280968
[No Abstract] [Full Text] [Related]
48. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
Feagan BG; Reinisch W; Rutgeerts P; Sandborn WJ; Yan S; Eisenberg D; Bala M; Johanns J; Olson A; Hanauer SB
Am J Gastroenterol; 2007 Apr; 102(4):794-802. PubMed ID: 17324131
[TBL] [Abstract][Full Text] [Related]
49. Adherence to Infliximab Treatment in a Pediatric Inflammatory Bowel Disease Cohort.
Vitale DS; Greenley RN; Lerner DG; Mavis AM; Werlin SL
J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):408-10. PubMed ID: 25885878
[TBL] [Abstract][Full Text] [Related]
50. Infliximab for refractory ulcerative proctitis.
Bouguen G; Roblin X; Bourreille A; Feier L; Filippi J; Nancey S; Bretagne JF; Flourié B; Hébuterne X; Bigard MA; Siproudhis L; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2010 Jun; 31(11):1178-85. PubMed ID: 20222911
[TBL] [Abstract][Full Text] [Related]
51. Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis.
Patel B; Butterfield JH; Weiler CR; Kane SV
Monoclon Antib Immunodiagn Immunother; 2016 Dec; 35(6):300-303. PubMed ID: 27911676
[TBL] [Abstract][Full Text] [Related]
52. Infliximab or cyclosporine for severe ulcerative colitis.
Järnerot G
Gastroenterology; 2006 Jan; 130(1):286; author reply 287. PubMed ID: 16401502
[No Abstract] [Full Text] [Related]
53. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
Iwasa R; Yamada A; Sono K; Furukawa R; Takeuchi K; Suzuki Y
BMC Gastroenterol; 2015 Aug; 15():103. PubMed ID: 26271624
[TBL] [Abstract][Full Text] [Related]
54. Infliximab for ulcerative colitis following liver transplantation.
Lal S; Steinhart AH
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):277-80. PubMed ID: 17301656
[TBL] [Abstract][Full Text] [Related]
55. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
56. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study.
Gustavsson A; Järnerot G; Hertervig E; Friis-Liby I; Blomquist L; Karlén P; Grännö C; Vilien M; Ström M; Verbaan H; Hellström PM; Magnuson A; Halfvarson J; Tysk C
Aliment Pharmacol Ther; 2010 Oct; 32(8):984-9. PubMed ID: 20937043
[TBL] [Abstract][Full Text] [Related]
57. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England.
Russo EA; Harris AW; Campbell S; Lindsay J; Hart A; Arebi N; Milestone A; Tsai HH; Walters J; Carpani M; Westaby D; Thillainayagam A; Bansi D; Ghosh S
Aliment Pharmacol Ther; 2009 Feb; 29(3):308-14. PubMed ID: 19035973
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
[TBL] [Abstract][Full Text] [Related]
59. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.
Tsukamoto H; Tanida S; Mizoshita T; Ozeki K; Ebi M; Shimura T; Mori Y; Kataoka H; Kamiya T; Joh T
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):714-8. PubMed ID: 23411870
[TBL] [Abstract][Full Text] [Related]
60. Infliximab for the treatment of acute exacerbations of ulcerative colitis.
Bryan S; Andronis L; Hyde C; Connock M; Fry-Smith A; Wang D
Health Technol Assess; 2010 May; 14 Suppl 1():9-15. PubMed ID: 20507798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]